---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-008617"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-26T00:52:01.827466+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# NYSE American accepts AIM ImmunoTech's plan to regain listing compliance; deadline June 11, 2026

## Summary
- Plan accepted under Sections 1003(a)(ii) and 1003(a)(iii) of NYSE American Company Guide.
- AIM has until June 11, 2026 to meet minimum stockholders' equity requirements.
- CEO Thomas K. Equels expressed confidence in executing the strategy.
- Company continues oncology and antiviral pipeline development alongside compliance efforts.

## SEC filing metadata
- accession: 0001493152-25-008617
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315225008617/0001493152-25-008617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315225008617/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-008617
- JSON: https://secwatch.observer/filing/0001493152-25-008617.json
- Plain text: https://secwatch.observer/filing/0001493152-25-008617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.